Dr Shahin Fesharaki appointed as Lupin Global Chief Scientific Officer
Dr Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Mumbai: Global pharma major Lupin Limited has announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin's global research and development efforts across branded, generics and specialty products. Commenting on the appointment, Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin said, "We are very pleased to welcome Shahin to...
Mumbai: Global pharma major Lupin Limited has announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin's global research and development efforts across branded, generics and specialty products.
Commenting on the appointment, Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin said, "We are very pleased to welcome Shahin to our leadership team. Shahin's exceptional track record in delivering brands and generics across developed and emerging markets will be valuable to us as we accelerate our evolution into complex generics and specialty while driving growth across all our major markets."
Read also: Vibha Paul Rishi appointed as non-executive director to Piramal Pharma Board of Directors
With nearly 30 years' experience in drug development in leading global pharmaceutical companies, Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Prior to that Dr. Fesharaki held various leadership positions in Teva, Allergan/Actavis, Watson Pharmaceuticals and Apotex. Dr. Fesharaki has extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.
Read also: Lupin bags USFDA approval for Mirabegron ER tablets to treat overactive bladder
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS) and women's health areas.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd